Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer

Abstract

Conspectus Magnetic resonance imaging (MRI) is a clinical imaging modality that provides high-resolution images of soft tissues, including cancerous lesions. Stable gadolinium­(III) chelates have been used as contrast agents (CA) in MRI to enhance the contrast between the tissues of interest and surrounding tissues for accurate diagnostic imaging. Magnetic resonance molecular imaging (MRMI) of cancer requires targeted CA to specifically elucidate cancer-associated molecular processes and can provide high-resolution delineation and characterization of cancer for precision medicine. The main challenge for MRMI is the lack of sufficient sensitivity to detect the low concentration of the cellular oncogenic markers. In addition, targeted CA must satisfy regulatory safety requirements prior to clinical development. Up to now, there is no FDA-approved targeted CA for MRMI of cancer. In this Account, we discuss the latest developments in the design and development of clinically translatable targeted CA for MRMI of cancer, with an emphasis on our own research. The primary limitation of MRMI can be overcome by designing small molecular targeted CA to target abundant cancer-specific targets found in the tumor microenvironment (TME). For example, aggressive tumors have a unique extracellular matrix (ECM) composed of oncoproteins, which can be used as targetable markers for MRMI. We have designed and prepared small peptide conjugates of clinical contrast agents, including Gd-DTPA and Gd-DOTA, to target fibrin-fibronectin clots in tumors. These small molecular CA have been effective in enhancing MRMI detection of solid tumors and have demonstrated the ability to detect submillimeter cancer micrometastases in mouse tumor models, exceeding the detection limit of current clinical imaging modalities. We have also identified extradomain B fibronectin (EDB-FN), an oncofetal subtype of fibronectin, as a promising TME target to leverage in the design and development of small peptide targeted CA for clinical translation. The expression level of EDB-FN is correlated with invasiveness of cancer cells and poor patient survival of multiple cancer types. ZD2 peptide with a sequence of seven amino acids (TVRTSAD) was identified to specifically bind to the EDB protein fragment. Several ZD2 conjugates of macrocyclic GBCA, including Gd-DOTA and Gd­(HP-DO3A), have been synthesized and tested in mouse tumor models. ZD2–N3-Gd­(HP-DO3A) (MT218) with a high r1 relaxivity was selected as the lead agent for clinical translation. The physicochemical properties and preclinical assessments of MT218 are summarized in this Account. MRMI of EDB-FN with MT218 can effectively detect invasive tumors of multiple cancers with risk-stratification and monitor tumor response to anticancer therapies in mouse models. Currently, MT218 is in clinical trials for precision cancer MRMI. Herein, we will show that using targeted MRI contrast agents specific to abundant TME biomarkers is a pragmatic solution for effective precision cancer imaging in high spatial resolution. ...

Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging

“…ZD2 specificity for EDB-FN has been validated and used in the development of a targeted gadolinium-based contrast agent ZD2-N3-Gd­(HP-DO3A), MT218, for magnetic resonance molecular imaging (MRMI) of cancer . MRMI with MT218 can distinguish between aggressive and nonaggressive cancers based on EDB-FN expression. , The ZD2 peptide has shown high specificity to bind to abundant EDB-FN in the tumor ECM for cancer molecular imaging in multiple cancer models. It is also a promising candidate for functionalizing nanoparticles for enhanced delivery of siRNA to regulate lncRNA DANCR in TNBC …”

Targeted Magnetic Resonance Imaging/Near‐Infrared Dual‐Modal Imaging and Ferroptosis/Starvation Therapy of Gastric Cancer with Peritoneal Metastasis

“…Previous studies have shown that compared with passive target delivery, decoration with active targeting ligands (including cRGD, RGD, or RGD2), which can actively identify specific receptors on the target cell, is efficient. [17] Wang et al [18] constructed a chain-like nanoprobe (APP-Ag2S-RGD) that can be used to identify tumor margins for precise tumor resection of PM. However, the efficiency of this targeted delivery is easily diminished, which is attributed to the non-specific uptake of nanoparticles by non-cancerous cells.…”

Smart Biomimetic Nanozymes for Precise Molecular Imaging: Application and Challenges

“…Studies have shown that MONs can mimic the characteristics of POD, CAT, and SOD. Among various MONs, MnO 2 nanostructures have attracted considerable attention as stimuli-responsive and biodegradable materials [ 150 , 151 ]. In the TME, MnO 2 can react with GSH, H + ions, and H 2 O 2 to generate Mn 2+ ions, playing multiple roles in tumor diagnosis and treatment.…”